Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BBIO
stocks logo

BBIO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
148.13M
+2418.34%
-0.662
-52.73%
169.69M
+45.49%
-0.647
-26.48%
196.25M
+77.5%
-0.550
-42.11%
Estimates Revision
The market is revising Upward the revenue expectations for BridgeBio Pharma, Inc. (BBIO) for FY2025, with the revenue forecasts being adjusted by 4.83% over the past three months. During the same period, the stock price has changed by 40.05%.
Revenue Estimates for FY2025
Revise Upward
up Image
+4.83%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+4.87%
In Past 3 Month
Stock Price
Go Up
up Image
+40.05%
In Past 3 Month
Wall Street analysts forecast BBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBIO is 83.13 USD with a low forecast of 64.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
Wall Street analysts forecast BBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBIO is 83.13 USD with a low forecast of 64.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
0 Hold
0 Sell
Strong Buy
Current: 74.760
sliders
Low
64.00
Averages
83.13
High
100.00
Current: 74.760
sliders
Low
64.00
Averages
83.13
High
100.00
Wells Fargo
Overweight
maintain
$76 -> $84
2025-11-11
Reason
Wells Fargo
Price Target
$76 -> $84
2025-11-11
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on BridgeBio to $84 from $76 and keeps an Overweight rating on the shares. The firm likes the setup for shares, as it thinks there is likely upside to Attruby estimates in 2026, potential to gain clarity on Tafamidis Gxs, which should remove a key overhang, and a high probability of success Phase 3 read out for infigratinib in achondroplasia in early 2026.
JPMorgan
Anupam Rama
maintain
$76 -> $77
2025-11-07
Reason
JPMorgan
Anupam Rama
Price Target
$76 -> $77
2025-11-07
maintain
Reason
JPMorgan analyst Anupam Rama raised the firm's price target on BridgeBio to $77 from $76 and keeps an Overweight rating on the shares. The firm updated the company's model.
Goldman Sachs
Buy
upgrade
$55 -> $100
2025-10-31
Reason
Goldman Sachs
Price Target
$55 -> $100
2025-10-31
upgrade
Buy
Reason
Goldman Sachs raised the firm's price target on BridgeBio to $100 from $55 and keeps a Buy rating on the shares. BridgeBio's Q3 results highlighted strong commercial momentum for Attruby, with U.S. sales of $108.1M, exceeding estimates and reflecting a 40% increase in prescriptions since August, the analyst tells investors in a research note. Management cited growing share among newly diagnosed ATTR-CM patients and reiterated a 30%-35% target, supported by continued investment in awareness and diagnosis expansion. With topline results from the PROPEL 3 achondroplasia study expected in early 2026 and a deepening commercial pipeline, BridgeBio's transition toward a multi-product, profitable biotech remains on track, offering further upside potential, the firm says.
Oppenheimer
Oppenheimer
Outperform
upgrade
$73 -> $81
2025-10-30
Reason
Oppenheimer
Oppenheimer
Price Target
$73 -> $81
2025-10-30
upgrade
Outperform
Reason
Oppenheimer raised the firm's price target on BridgeBio to $81 from $73 and keeps an Outperform rating on the shares. The firm notes U.S. Attruby revenue of $108M surpassed its/Street's expectations of $106/95M. Ex-U.S. sales contributed $4.3M in royalty revenue. Oppenheimer says there could be some slight adherence headwinds developing over time as patients may come off drug without noticing benefit, though this is built into its $1B 2026 Attruby sales expectations. Shares may take a breather after this week's +13% move, but the firm remains Outperform-rated and would be buying into infigratinib's early 2026's readout.
TD Cowen
NULL -> Buy
upgrade
$60 -> $95
2025-10-30
Reason
TD Cowen
Price Target
$60 -> $95
2025-10-30
upgrade
NULL -> Buy
Reason
TD Cowen raised the firm's price target on BridgeBio to $95 from $60 and keeps a Buy rating on the shares. The firm said the 51% quarter-over-quarter Attruby sales growth beat expectations and was driven by treatment naive patients and accelerating new patient prescriptions. BridgeBio remains focused on the Attruby launch and the late-stage pipeline and is two-for-two so far with positive LGMD and ADH1 readouts set to be released.
Truist
NULL -> Buy
upgrade
$66 -> $80
2025-10-30
Reason
Truist
Price Target
$66 -> $80
2025-10-30
upgrade
NULL -> Buy
Reason
Truist raised the firm's price target on BridgeBio to $80 from $66 and keeps a Buy rating on the shares. The firm has updated its model to reflect Attruby performance in Q3, positive Phase 3 data in ribitol in LGMD2I/R9, and positive Phase 3 data in encaleret in ADH1, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for BridgeBio Pharma Inc (BBIO.O) is -32.35, compared to its 5-year average forward P/E of -9.61. For a more detailed relative valuation and DCF analysis to assess BridgeBio Pharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.61
Current PE
-32.35
Overvalued PE
-3.59
Undervalued PE
-15.64

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-15.12
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-4.14
Undervalued EV/EBITDA
-26.09

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
84.56
Current PS
0.00
Overvalued PS
159.90
Undervalued PS
9.23
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress areBuying! The buying amount has increased100%over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

BBIO News & Events

Events Timeline

(ET)
2025-11-09
13:10:26
BridgeBio shares findings from the ATTRibute-CM study regarding acoramidis.
select
2025-10-29 (ET)
2025-10-29
16:08:03
BridgeBio announces Q3 earnings per share of 95 cents, surpassing consensus estimate of 78 cents.
select
2025-10-29
07:15:26
BridgeBio reports successful achievement of primary endpoint in Phase 3 study of encaleret.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-28NASDAQ.COM
BridgeBio (BBIO) Transcript of Q3 2025 Earnings Call
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
[object Object]
Preview
1.0
11-25Newsfilter
BridgeBio Pharma to Participate in Two Investor Conferences
  • Investor Conference Participation: BridgeBio Pharma will participate in a fireside chat at the Piper Sandler Healthcare Conference in New York on December 2 at 10:30 AM EST, showcasing its innovations in genetic diseases.
  • Strategic Presentation: Following this, BridgeBio will engage in another fireside chat at the EvercoreISI HealthCONx Conference in Miami on December 3 at 3:00 PM EST, further enhancing the company's visibility among investors.
  • Live Webcast Availability: The company will provide live streaming and a 90-day replay of the presentations on its website, ensuring investors have timely access to key information and enhancing transparency.
  • Company Background: Founded in 2015, BridgeBio Pharma focuses on developing transformative medicines for genetic diseases, with a pipeline that spans from early science to advanced clinical trials, demonstrating its potential in the biopharmaceutical sector.
[object Object]
Preview
8.0
11-12NASDAQ.COM
Noteworthy BBIO Put and Call Options Set for April 2026

  • Put Contract Overview: The $65.00 put contract for BBIO has a bid of $7.20, allowing investors to purchase shares at a cost basis of $57.80, which is attractive compared to the current price of $67.54. There is a 62% chance the contract may expire worthless, potentially yielding an 11.08% return on cash commitment.

  • Call Contract Overview: The $70.00 call contract has a bid of $7.00, and if shares are purchased at $67.54 and the call is sold, it could yield a total return of 14.01% if exercised by April 2026. There is a 46% chance this contract may also expire worthless, allowing the investor to keep both the shares and the premium.

  • Volatility Insights: The implied volatility for the put contract is 63%, while for the call contract it is 57%. The actual trailing twelve-month volatility is calculated at 53%, providing context for the options' pricing.

  • YieldBoost Concept: Both the put and call contracts offer potential YieldBoosts, with the put providing an 11.08% return and the call offering a 10.36% boost if they expire worthless, highlighting the benefits of these options strategies for investors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is BridgeBio Pharma Inc (BBIO) stock price today?

The current price of BBIO is 74.76 USD — it has increased 0.82 % in the last trading day.

arrow icon

What is BridgeBio Pharma Inc (BBIO)'s business?

BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.

arrow icon

What is the price predicton of BBIO Stock?

Wall Street analysts forecast BBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBIO is 83.13 USD with a low forecast of 64.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is BridgeBio Pharma Inc (BBIO)'s revenue for the last quarter?

BridgeBio Pharma Inc revenue for the last quarter amounts to 120.70M USD, increased 4318.01 % YoY.

arrow icon

What is BridgeBio Pharma Inc (BBIO)'s earnings per share (EPS) for the last quarter?

BridgeBio Pharma Inc. EPS for the last quarter amounts to -0.95 USD, increased 10.47 % YoY.

arrow icon

What changes have occurred in the market's expectations for BridgeBio Pharma Inc (BBIO)'s fundamentals?

The market is revising Upward the revenue expectations for BridgeBio Pharma, Inc. (BBIO) for FY2025, with the revenue forecasts being adjusted by 4.83% over the past three months. During the same period, the stock price has changed by 40.05%.
arrow icon

How many employees does BridgeBio Pharma Inc (BBIO). have?

BridgeBio Pharma Inc (BBIO) has 725 emplpoyees as of December 05 2025.

arrow icon

What is BridgeBio Pharma Inc (BBIO) market cap?

Today BBIO has the market capitalization of 14.41B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free